ApoCIII: A multifaceted protein in cardiometabolic disease
- PMID: 33058850
- DOI: 10.1016/j.metabol.2020.154395
ApoCIII: A multifaceted protein in cardiometabolic disease
Abstract
ApoCIII has a well-recognized role in triglyceride-rich lipoproteins metabolism. A considerable amount of data has clearly highlighted that high levels of ApoCIII lead to hypertriglyceridemia and, thereby, may influence the risk of cardiovascular disease. However, recent findings indicate that ApoCIII might also act beyond lipid metabolism. Indeed, ApoCIII has been implicated in other physiological processes such as glucose homeostasis, monocyte adhesion, activation of inflammatory pathways, and modulation of the coagulation cascade. As the inhibition of ApoCIII is emerging as a new promising therapeutic strategy, the complete understanding of multifaceted pathophysiological role of this apoprotein may be relevant. Therefore, the purpose of this work is to review available evidences not only related to genetics and biochemistry of ApoCIII, but also highlighting the role of this apoprotein in triglyceride and glucose metabolism, in the inflammatory process and coagulation cascade as well as in cardiovascular disease.
Keywords: APOC3 gene; APOC3 gene expression; ApoCIII protein; Cardiovascular disease risk; Therapeutic target; Triglycerides; Triglycerides (TG)-rich lipoproteins (TRL).
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest LD has received personal fees for public speaking, consultancy or grant support from Amryt Pharmaceuticals, Akcea Therapeutics, Pfizer, Amgen and Sanofi; MA has received research grant support from Amryth Pharmaceutical, Amgen, IONIS, Akcea Therapeutics, Pfizer and Sanofi; has served as a consultant for Amgen, Aegerion, Akcea Therapeutics, Regeneron, Sanofi and Alfasigma and received lecturing fees from Amgen, Amryth Pharmaceutical, Pfizer, Sanofi and AlfaSigma; AG has received personal fees for public speaking or consultancy support from Akcea Therapeutics, AMGEN, MSD, Mylan, Novartis, Sanofi and Regeneron, Unilever; EB has received honoraria from AMGEN, MSD, Sanofi and Regeneron, Unilever, Danone, Aegerion, Chiesi, Rottapharm-MEDA, Servier, Ionis-pharmaceuticals, AKCEA and MYLAN. ADC does not have any potential conflict of interest.
Similar articles
-
ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.Curr Atheroscler Rep. 2017 Nov 9;19(12):62. doi: 10.1007/s11883-017-0697-3. Curr Atheroscler Rep. 2017. PMID: 29124482 Review.
-
Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII.Cardiovasc Res. 2015 Sep 1;107(4):579-89. doi: 10.1093/cvr/cvv192. Epub 2015 Jul 9. Cardiovasc Res. 2015. PMID: 26160324
-
Recent Apolipoprotein CIII trials.Curr Opin Lipidol. 2022 Dec 1;33(6):309-318. doi: 10.1097/MOL.0000000000000849. Epub 2022 Sep 28. Curr Opin Lipidol. 2022. PMID: 36206093 Review.
-
Increased inflammation, endoplasmic reticulum stress and oxidative stress in endothelial and macrophage cells exacerbate atherosclerosis in ApoCIII transgenic mice.Lipids Health Dis. 2018 Sep 17;17(1):220. doi: 10.1186/s12944-018-0867-5. Lipids Health Dis. 2018. PMID: 30223835 Free PMC article.
-
Association of the S2 allele of the SstI polymorphism in the apoC3 gene with plasma apoCIII interacts with unfavorable lipid profiles to contribute to atherosclerosis in the Li ethnic group in China.Lipids Health Dis. 2017 Nov 21;16(1):220. doi: 10.1186/s12944-017-0614-3. Lipids Health Dis. 2017. PMID: 29162127 Free PMC article.
Cited by
-
Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling.Clin Proteomics. 2024 Mar 1;21(1):19. doi: 10.1186/s12014-024-09465-w. Clin Proteomics. 2024. PMID: 38429638 Free PMC article. Review.
-
A novel lncRNA GM47544 modulates triglyceride metabolism by inducing ubiquitination-dependent protein degradation of APOC3.Mol Metab. 2024 Oct;88:102011. doi: 10.1016/j.molmet.2024.102011. Epub 2024 Aug 20. Mol Metab. 2024. PMID: 39173944 Free PMC article.
-
Efficacy and Safety of Olezarsen in Dyslipidemia: A Systematic Review and Dose-response Meta-analysis of Randomized Controlled Trials.J Saudi Heart Assoc. 2025 Jun 12;37(3):3. doi: 10.37616/2212-5043.1439. eCollection 2025. J Saudi Heart Assoc. 2025. PMID: 40557417 Free PMC article. Review.
-
Apolipoproteins as potential communicators play an essential role in the pathogenesis and treatment of early atherosclerosis.Int J Biol Sci. 2023 Aug 21;19(14):4493-4510. doi: 10.7150/ijbs.86475. eCollection 2023. Int J Biol Sci. 2023. PMID: 37781031 Free PMC article. Review.
-
Triglyceride-independent associations between circulating levels of apolipoprotein C-III and biomarkers of inflammation.Cardiovasc Diabetol. 2025 Jan 8;24(1):9. doi: 10.1186/s12933-024-02553-z. Cardiovasc Diabetol. 2025. PMID: 39780204 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous